Predicting the Risk of New Cerebral Lesions After Stereotactic Radiosurgery (SRS) for Brain Metastases from Breast Cancer

Liesa Dziggel, Markus Dahlke, Stefan Janssen, Dagmar Hornung, Oliver Blanck, Mai T rong Khoa, Steven E. Schild, Dirk Rades

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

AIM: To generate a tool that estimates the probability of developing new cerebral metastases after stereotactic radiosurgery (SRS) in breast cancer patients.

PATIENTS AND METHODS: SRS dose plus seven characteristics (age, performance score, number of cerebral metastases, maximum diameter of all metastases, location of metastases, extra-cerebral spread and time from breast cancer diagnosis until SRS) were analyzed regarding their ability to predict the probability of new cerebral metastases development following SRS. For those characteristics deemed significant, points of 0 (higher risk of new lesions) or 1 (lower risk) were given. Scores were generated by adding the points of significant characteristics.

RESULTS: Performance score (p=0.013) and maximum diameter of all metastases (p=0.022) were associated with development of subsequent brain metastases. Two groups were created, 0-1 and 2 points. Freedom from new cerebral metastases rates were 27% and 92%, respectively, at 15 months (p=0.003).

CONCLUSION: This tool helps select breast cancer with few cerebral metastases receiving SRS who may benefit from additional whole-brain irradiation.

Original languageEnglish (US)
Pages (from-to)6793-6797
Number of pages5
JournalAnticancer Research
Volume35
Issue number12
StatePublished - Dec 1 2015

Fingerprint

Radiosurgery
Breast Neoplasms
Neoplasm Metastasis
Brain

Keywords

  • breast cancer
  • Cerebral metastases
  • freedom from new cerebral metastases
  • prognostic tool
  • stereotactic radiosurgery

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Dziggel, L., Dahlke, M., Janssen, S., Hornung, D., Blanck, O., Khoa, M. T. R., ... Rades, D. (2015). Predicting the Risk of New Cerebral Lesions After Stereotactic Radiosurgery (SRS) for Brain Metastases from Breast Cancer. Anticancer Research, 35(12), 6793-6797.

Predicting the Risk of New Cerebral Lesions After Stereotactic Radiosurgery (SRS) for Brain Metastases from Breast Cancer. / Dziggel, Liesa; Dahlke, Markus; Janssen, Stefan; Hornung, Dagmar; Blanck, Oliver; Khoa, Mai T rong; Schild, Steven E.; Rades, Dirk.

In: Anticancer Research, Vol. 35, No. 12, 01.12.2015, p. 6793-6797.

Research output: Contribution to journalArticle

Dziggel, L, Dahlke, M, Janssen, S, Hornung, D, Blanck, O, Khoa, MTR, Schild, SE & Rades, D 2015, 'Predicting the Risk of New Cerebral Lesions After Stereotactic Radiosurgery (SRS) for Brain Metastases from Breast Cancer', Anticancer Research, vol. 35, no. 12, pp. 6793-6797.
Dziggel L, Dahlke M, Janssen S, Hornung D, Blanck O, Khoa MTR et al. Predicting the Risk of New Cerebral Lesions After Stereotactic Radiosurgery (SRS) for Brain Metastases from Breast Cancer. Anticancer Research. 2015 Dec 1;35(12):6793-6797.
Dziggel, Liesa ; Dahlke, Markus ; Janssen, Stefan ; Hornung, Dagmar ; Blanck, Oliver ; Khoa, Mai T rong ; Schild, Steven E. ; Rades, Dirk. / Predicting the Risk of New Cerebral Lesions After Stereotactic Radiosurgery (SRS) for Brain Metastases from Breast Cancer. In: Anticancer Research. 2015 ; Vol. 35, No. 12. pp. 6793-6797.
@article{b37b1d6d147f405db799c756ed28477a,
title = "Predicting the Risk of New Cerebral Lesions After Stereotactic Radiosurgery (SRS) for Brain Metastases from Breast Cancer",
abstract = "AIM: To generate a tool that estimates the probability of developing new cerebral metastases after stereotactic radiosurgery (SRS) in breast cancer patients.PATIENTS AND METHODS: SRS dose plus seven characteristics (age, performance score, number of cerebral metastases, maximum diameter of all metastases, location of metastases, extra-cerebral spread and time from breast cancer diagnosis until SRS) were analyzed regarding their ability to predict the probability of new cerebral metastases development following SRS. For those characteristics deemed significant, points of 0 (higher risk of new lesions) or 1 (lower risk) were given. Scores were generated by adding the points of significant characteristics.RESULTS: Performance score (p=0.013) and maximum diameter of all metastases (p=0.022) were associated with development of subsequent brain metastases. Two groups were created, 0-1 and 2 points. Freedom from new cerebral metastases rates were 27{\%} and 92{\%}, respectively, at 15 months (p=0.003).CONCLUSION: This tool helps select breast cancer with few cerebral metastases receiving SRS who may benefit from additional whole-brain irradiation.",
keywords = "breast cancer, Cerebral metastases, freedom from new cerebral metastases, prognostic tool, stereotactic radiosurgery",
author = "Liesa Dziggel and Markus Dahlke and Stefan Janssen and Dagmar Hornung and Oliver Blanck and Khoa, {Mai T rong} and Schild, {Steven E.} and Dirk Rades",
year = "2015",
month = "12",
day = "1",
language = "English (US)",
volume = "35",
pages = "6793--6797",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "12",

}

TY - JOUR

T1 - Predicting the Risk of New Cerebral Lesions After Stereotactic Radiosurgery (SRS) for Brain Metastases from Breast Cancer

AU - Dziggel, Liesa

AU - Dahlke, Markus

AU - Janssen, Stefan

AU - Hornung, Dagmar

AU - Blanck, Oliver

AU - Khoa, Mai T rong

AU - Schild, Steven E.

AU - Rades, Dirk

PY - 2015/12/1

Y1 - 2015/12/1

N2 - AIM: To generate a tool that estimates the probability of developing new cerebral metastases after stereotactic radiosurgery (SRS) in breast cancer patients.PATIENTS AND METHODS: SRS dose plus seven characteristics (age, performance score, number of cerebral metastases, maximum diameter of all metastases, location of metastases, extra-cerebral spread and time from breast cancer diagnosis until SRS) were analyzed regarding their ability to predict the probability of new cerebral metastases development following SRS. For those characteristics deemed significant, points of 0 (higher risk of new lesions) or 1 (lower risk) were given. Scores were generated by adding the points of significant characteristics.RESULTS: Performance score (p=0.013) and maximum diameter of all metastases (p=0.022) were associated with development of subsequent brain metastases. Two groups were created, 0-1 and 2 points. Freedom from new cerebral metastases rates were 27% and 92%, respectively, at 15 months (p=0.003).CONCLUSION: This tool helps select breast cancer with few cerebral metastases receiving SRS who may benefit from additional whole-brain irradiation.

AB - AIM: To generate a tool that estimates the probability of developing new cerebral metastases after stereotactic radiosurgery (SRS) in breast cancer patients.PATIENTS AND METHODS: SRS dose plus seven characteristics (age, performance score, number of cerebral metastases, maximum diameter of all metastases, location of metastases, extra-cerebral spread and time from breast cancer diagnosis until SRS) were analyzed regarding their ability to predict the probability of new cerebral metastases development following SRS. For those characteristics deemed significant, points of 0 (higher risk of new lesions) or 1 (lower risk) were given. Scores were generated by adding the points of significant characteristics.RESULTS: Performance score (p=0.013) and maximum diameter of all metastases (p=0.022) were associated with development of subsequent brain metastases. Two groups were created, 0-1 and 2 points. Freedom from new cerebral metastases rates were 27% and 92%, respectively, at 15 months (p=0.003).CONCLUSION: This tool helps select breast cancer with few cerebral metastases receiving SRS who may benefit from additional whole-brain irradiation.

KW - breast cancer

KW - Cerebral metastases

KW - freedom from new cerebral metastases

KW - prognostic tool

KW - stereotactic radiosurgery

UR - http://www.scopus.com/inward/record.url?scp=84973409090&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973409090&partnerID=8YFLogxK

M3 - Article

C2 - 26637898

AN - SCOPUS:84973409090

VL - 35

SP - 6793

EP - 6797

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 12

ER -